Recent studies have found that PCSK9 inhibitorscan induce hyperlipidemia and lead to atherosclerosisby promoting lysosomal degradation of LDL-R in theliver, which hinders the process of LDL-C clearance.PCSK9 inhibitors can bind to PCSK9, preventing itfrom binding to LDL-R and avoiding the decompositionof LDL-R, thereby increasing the uptake of LDL-Cin the liver and reducing its concentration in theblood [11]. The gene discussed is LDLR; the disease is hyperlipidemia.